SLC2A4 and Hyperinsulinemia: Several studies also indicate that P-LAP siRNA (an inhibitor of hyperinsulinemia) may be a potential agent of molecular-targeted therapy for EC via the downregulation of GLUT4 expression and the prevention of tumor cells’ proliferation and angiogenesis (133).